Sanofi (SNY)
NASDAQ: SNY · Real-Time Price · USD
47.20
+0.70 (1.51%)
At close: Jan 23, 2026, 4:00 PM EST
47.30
+0.10 (0.21%)
After-hours: Jan 23, 2026, 7:48 PM EST
Sanofi Employees
Sanofi had 82,878 employees as of December 31, 2024. The number of employees decreased by 3,210 or -3.73% compared to the previous year.
Employees
82,878
Change (1Y)
-3,210
Growth (1Y)
-3.73%
Revenue / Employee
$650,241
Profits / Employee
$129,012
Market Cap
112.73B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 82,878 | -3,210 | -3.73% |
| Dec 31, 2023 | 86,088 | -5,485 | -5.99% |
| Dec 31, 2022 | 91,573 | -3,869 | -4.05% |
| Dec 31, 2021 | 95,442 | -3,970 | -3.99% |
| Dec 31, 2020 | 99,412 | -997 | -0.99% |
| Dec 31, 2019 | 100,409 | -3,817 | -3.66% |
| Dec 31, 2018 | 104,226 | -2,340 | -2.20% |
| Dec 31, 2017 | 106,566 | -293 | -0.27% |
| Dec 31, 2016 | 106,859 | -2,230 | -2.04% |
| Dec 31, 2015 | 109,089 | 1,702 | 1.58% |
| Dec 31, 2014 | 107,387 | -4,741 | -4.23% |
| Dec 31, 2013 | 112,128 | 154 | 0.14% |
| Dec 31, 2012 | 111,974 | -1,745 | -1.53% |
| Dec 31, 2011 | 113,719 | 12,144 | 11.96% |
| Dec 31, 2010 | 101,575 | -3,292 | -3.14% |
| Dec 31, 2009 | 104,867 | 6,654 | 6.78% |
| Dec 31, 2008 | 98,213 | -1,282 | -1.29% |
| Dec 31, 2007 | 99,495 | -794 | -0.79% |
| Dec 31, 2006 | 100,289 | 3,108 | 3.20% |
| Dec 31, 2005 | 97,181 | 742 | 0.77% |
| Dec 31, 2004 | 96,439 | 63,353 | 191.48% |
| Dec 31, 2003 | 33,086 | 650 | 2.00% |
| Dec 31, 2002 | 32,436 | 1,922 | 6.30% |
| Dec 31, 2001 | 30,514 | 1,314 | 4.50% |
| Dec 31, 2000 | 29,200 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 92,900 |
| Pfizer | 81,000 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| GSK plc | 68,629 |
| AbbVie | 55,000 |
| Bristol-Myers Squibb Company | 34,100 |
SNY News
- 23 hours ago - Sanofi Says Its Amlitelimab Drug Showed Promising Results in Treating Eczema - WSJ
- 23 hours ago - Press Release: Sanofi's amlitelimab confirms its potential in atopic dermatitis - GlobeNewsWire
- 8 days ago - Press Release: Myqorzo and Redemplo approved in China - GlobeNewsWire
- 9 days ago - Sanofi sees softness in U.S. vaccine demand in near term - Reuters
- 9 days ago - Sanofi: Information concerning the total number of voting rights and shares - December 2025 - GlobeNewsWire
- 11 days ago - Sanofi (SAN:CA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 11 days ago - Recludix Pharma Announces Dosing of First Subjects in a Phase 1 Study of REX-8756, a Potent and Selective Oral STAT6 Inhibitor, and Achieves Associated $20 Million Milestone Payment Under Collaboration with Sanofi - GlobeNewsWire
- 11 days ago - Press Release: Sanofi's Teizeild approved in the EU for patients with stage 2 type 1 diabetes - GlobeNewsWire